News & Events

Client News

VectorY Announces Preclinical Data on   TDP-43 and Oxidized Phospholipids at  American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

18 May 2022
VectorY Announces Preclinical Data on TDP-43 and Oxidized Phospholipids at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

18 May 2022
EpiEndo: Successful completion of Phase I Study for lead asset EP395

09 May 2022
Dr Isaac Cohen and Dr Eugen Steiner appointed to EpiEndo’s Board of Directors

05 May 2022
Oxford BioDynamics presents clear clinical utility data of the Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) at ASCO 2022, June 3-7

25 April 2022
Porton Advanced and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Cell Therapy Development for Solid Tumors

21 April 2022
EpiEndo expands operations with new facility in Sweden’s largest life science cluster

14 April 2022
Poolbeg Pharma plc - Key POLB 002 European Patent Granted

14 April 2022
New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens

05 April 2022
Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic

31 March 2022
Mission Therapeutics authorised to initiate first clinical trial for lead DUB program, MTX652, in kidney disease

31 March 2022
Poolbeg Pharma plc- POLB 001 Clinical Development - Clinical Trial Agreement Signed

30 March 2022
Tetris Pharma Appoints Brocacef to Provide Storage and Distribution Services, Further Building its Pan-European Platform

24 March 2022
Poolbeg Pharma plc - Artificial Intelligence deal signed with CytoReason

24 March 2022
EpiEndo Pharmaceuticals appoints Stefan Petursson as CFO to support future growth

23 March 2022
HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer

21 March 2022
Ixaka expands IP portfolio to enable use of targeted nanoparticle in vivo gene delivery technology with any cargo in any therapeutic area

14 March 2022
Seventure Partners: 2022 to see continued growth in the microbiome and “beyond-the-pill” sector

09 March 2022
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology

08 March 2022
CELTIC-19 granted Advanced Therapy Medicinal Product classification by European Medicines Agency

07 March 2022
Microbiotica raises £50M ($67M) to advance pipeline of microbiome-based therapeutics

02 March 2022
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

02 March 2022
Tetris Pharma Ltd announces its partnership with Primex Pharmaceuticals for the exclusive supply and distribution of a licensed product used in paediatrics for pre-anaesthesia and diagnostic testing in the UK.

01 March 2022
Touchlight and Versameb announce GMP manufacturing supply agreement

25 February 2022
Oxford BioDynamics announces US launch of its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) for oncology

24 February 2022
Poolbeg Pharma plc - Artificial Intelligence deal signed with OneThree Biotech

17 February 2022
SkinBioTherapeutics plc Business update 2022

16 February 2022
HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV

15 February 2022
Tetris Pharma Builds Out Pan-European Platform, Appointing Sharp to Support Packaging Needs

14 February 2022
Merit wins £30m Piramal’s Antibody Drug Conjugate manufacturing facility expansion project

11 February 2022
Seventure Partners expands focus to ‘blue’ economy BlueForwardFund™ announces first close, with the support of the Banque Populaire banks

11 February 2022
Ixaka Expands Management Team with Multiple Appointments

08 February 2022
AskBio and Touchlight Restructure Joint Venture

03 February 2022
Enthera Pharmaceuticals, Boston Children’s Hospital of the Harvard Medical School and the University of Milan reveal use of novel pathway to restore pancreatic cell function in diabetes in Nature Communications

02 February 2022
NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease

31 January 2022
Poolbeg Pharma - Confirmation that the licence to develop oral vaccine delivery platform has been executed

25 January 2022
Oxford Biodynamics Plc - Full Year Results 2021

25 January 2022
VectorY and Wageningen University sign strategic collaboration for the development of novel baculovirus-based AAV production technologies

18 January 2022
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation

18 January 2022
SkinBioTherapeutics plc - Searches commence for full time CFO and for new non-executive director with ecommerce and digital marketing background

17 January 2022
Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick

12 January 2022
Tetris Pharma Strengthens Leadership Team with Multiple Appointments to Support Pan-European Platform Approach

11 January 2022
GHO Capital invests in RoslinCT, a leading cell therapy CDMO

10 January 2022
BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies